Gene methylation in pleural mesothelioma: correlations with clinico-pathological features and patient's follow-up.

[1]  S. Toyooka,et al.  Aberrant promoter methylation of insulin‐like growth factor binding protein‐3 gene in human cancers , 2007, International journal of cancer.

[2]  D. Fennell,et al.  In vivo Loss of Expression of Argininosuccinate Synthetase in Malignant Pleural Mesothelioma Is a Biomarker for Susceptibility to Arginine Depletion , 2006, Clinical Cancer Research.

[3]  G. Giaccone,et al.  Biology and management of malignant pleural mesothelioma. , 2006, European journal of cancer.

[4]  Ming Zhao,et al.  Phase I Study of Decitabine-Mediated Gene Expression in Patients with Cancers Involving the Lungs, Esophagus, or Pleura , 2006, Clinical Cancer Research.

[5]  Marius Žemaitis,et al.  Promoter methylation of RASSF1A, RARbeta and DAPK predict poor prognosis of patients with malignant mesothelioma. , 2006, Lung cancer.

[6]  J. Decaprio,et al.  Is there a role for SV40 in human cancer? , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  N. Reguart,et al.  Wnt inhibitory factor-1, a Wnt antagonist, is silenced by promoter hypermethylation in malignant pleural mesothelioma. , 2006, Biochemical and biophysical research communications.

[8]  M. Roncalli,et al.  Quantitative evaluation of RASSF1A methylation in the non-lesional, regenerative and neoplastic liver , 2006, BMC Cancer.

[9]  A. Ceribelli,et al.  Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  G. Ceresoli,et al.  EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations. , 2006, Lung cancer.

[11]  S. Baylin,et al.  Epigenetic gene silencing in cancer – a mechanism for early oncogenic pathway addiction? , 2006, Nature Reviews Cancer.

[12]  B. Robinson,et al.  Advances in malignant mesothelioma. , 2005, The New England journal of medicine.

[13]  N. Sharpless,et al.  INK4a/ARF: a multifunctional tumor suppressor locus. , 2005, Mutation research.

[14]  D. Maziak,et al.  Surgical management of malignant pleural mesothelioma: a systematic review and evidence summary. , 2005, Lung cancer.

[15]  S. Toyooka,et al.  Aberrant methylation of HIN‐1 (high in normal‐1) is a frequent event in many human malignancies , 2005, International journal of cancer.

[16]  S. Toyooka,et al.  Aberrant methylation profile of human malignant mesotheliomas and its relationship to SV40 infection , 2005, Oncogene.

[17]  Amie Y Lee,et al.  Secreted frizzled-related protein 4 is silenced by hypermethylation and induces apoptosis in beta-catenin-deficient human mesothelioma cells. , 2005, Cancer research.

[18]  M. Fraga,et al.  CpG island promoter hypermethylation of the Ras-effector gene NORE1A occurs in the context of a wild-type K-ras in lung cancer , 2004, Oncogene.

[19]  S. Toyooka,et al.  Aberrant methylation of p57KIP2 gene in lung and breast cancers and malignant mesotheliomas. , 2004, Oncology reports.

[20]  Biao He,et al.  Expression of the secreted frizzled-related protein gene family is downregulated in human mesothelioma , 2004, Oncogene.

[21]  S. Toyooka,et al.  Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor types , 2004, International journal of cancer.

[22]  A. Marchetti,et al.  K-ras and p16(INK4A)alterations in sputum of NSCLC patients and in heavy asymptomatic chronic smokers. , 2004, Lung cancer.

[23]  J. Herman,et al.  Gene silencing in cancer in association with promoter hypermethylation. , 2003, The New England journal of medicine.

[24]  Biao He,et al.  SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[25]  P. Laird,et al.  Distinct DNA methylation profiles in malignant mesothelioma, lung adenocarcinoma, and non-tumor lung. , 2003, Lung cancer.

[26]  Claude Denham,et al.  Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  G. Scagliotti,et al.  Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  J. Minna,et al.  NORE1A, a homologue of RASSF1A tumour suppressor gene is inactivated in human cancers , 2003, Oncogene.

[29]  R. Kratzke,et al.  Inactivation of p16INK4a expression in malignant mesothelioma by methylation. , 2002, Lung cancer.

[30]  G. Gordon,et al.  Alterations of the p16(INK4) locus in human malignant mesothelial tumors. , 2002, Carcinogenesis.

[31]  G. Pfeifer,et al.  Methylation of the RASSF1A Gene in Human Cancers , 2002, Biological chemistry.

[32]  J. Minna,et al.  Progressive aberrant methylation of the RASSF1A gene in simian virus 40 infected human mesothelial cells , 2002, Oncogene.

[33]  M. Carbone,et al.  The Role of Environmental Carcinogens, Viruses, and Genetic , 2002, Cancer biology & therapy.

[34]  J. Herman,et al.  Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours , 2002, The Journal of pathology.

[35]  J. Minna,et al.  Aberrant methylation and simian virus 40 tag sequences in malignant mesothelioma. , 2001, Cancer research.

[36]  J. Minna,et al.  Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours , 2001, Oncogene.

[37]  S. Jhanwar,et al.  Expression of GPC3, an X-linked recessive overgrowth gene, is silenced in malignant mesothelioma , 2000, Oncogene.

[38]  J. Testa,et al.  Asbestos, chromosomal deletions, and tumor suppressor gene alterations in human malignant mesothelioma , 1999, Journal of cellular physiology.

[39]  Y. Shimosato,et al.  Histological Typing of Lung and Pleural Tumours , 1999, World Health Organization.

[40]  J. Herndon,et al.  Dihydro‐5‐azacytidine and cisplatin in the treatment of malignant mesothelioma , 1998, Cancer.

[41]  T. H. van der Kwast,et al.  The gene for the cyclin‐dependent‐kinase‐4 inhibitor, CDKN2A, is preferentially deleted in malignant mesothelioma , 1998, International journal of cancer.

[42]  M. Citron,et al.  Dihydro‐5‐azacytidine in malignant mesothelioma , 1997, Cancer.

[43]  J. Herman,et al.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[44]  F. Kaye,et al.  Immunohistochemical analysis of the p16INK4 cyclin-dependent kinase inhibitor in malignant mesothelioma. , 1995, Journal of the National Cancer Institute.

[45]  J. Fletcher,et al.  Codeletion of p15 and p16 in primary malignant mesothelioma. , 1995, Oncogene.

[46]  J. Fletcher,et al.  Codeletion of p15 and p16 genes in primary non-small cell lung carcinoma. , 1995, Cancer research.

[47]  O. Olopade,et al.  p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. , 1994, Cancer research.

[48]  G. Hannon,et al.  A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 , 1993, Nature.

[49]  W. Richards,et al.  Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. , 1999, The Journal of thoracic and cardiovascular surgery.

[50]  J. Testa,et al.  Somatic genetic alterations in human malignant mesothelioma (review). , 1999, International journal of oncology.